{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T19:06:46Z","timestamp":1761419206233,"version":"3.37.3"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T00:00:00Z","timestamp":1526428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001254","name":"Ipsen Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001254","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s12020-018-1615-3","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T06:29:14Z","timestamp":1526452154000},"page":"105-117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis"],"prefix":"10.1007","volume":"61","author":[{"given":"Whitney W.","family":"Woodmansee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray B.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Molitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana G.","family":"Ioachimescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don W.","family":"Carver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beloo","family":"Mirakhur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Salvatori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,16]]},"reference":[{"issue":"3","key":"1615_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s11102-015-0701-2","volume":"19","author":"T Burton","year":"2016","unstructured":"T. Burton, E. Le Nestour, M. Neary, W.H. Ludlam, Incidence and prevalence of acromegaly in a large US health plan database. Pituitary 19(3), 262\u2013267 (2016). \n                    https:\/\/doi.org\/10.1007\/s11102-015-0701-2","journal-title":"Pituitary"},{"issue":"3","key":"1615_CR2","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s11102-012-0420-x","volume":"16","author":"S Melmed","year":"2013","unstructured":"S. Melmed, F.F. Casanueva, A. Klibanski, M.D. Bronstein, P. Chanson, S.W. Lamberts, C.J. Strasburger, J.A. Wass, A. Giustina, A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16(3), 294\u2013302 (2013). \n                    https:\/\/doi.org\/10.1007\/s11102-012-0420-x","journal-title":"Pituitary"},{"issue":"5","key":"1615_CR3","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1210\/jc.2008-2421","volume":"94","author":"S Melmed","year":"2009","unstructured":"S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M.L. Vance, K. Ho, A. Giustina, Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94(5), 1509\u20131517 (2009). \n                    https:\/\/doi.org\/10.1210\/jc.2008-2421","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1615_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP.17.S4.1","volume":"17","author":"L Katznelson","year":"2011","unstructured":"L. Katznelson, J.L. Atkinson, D.M. Cook, S.Z. Ezzat, A.H. Hamrahian, K.K. Miller, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly\u20142011 update. Endocr. Pract. 17, 1\u201344 (2011).","journal-title":"Endocr. Pract."},{"issue":"7","key":"1615_CR5","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1210\/jc.2009-2670","volume":"95","author":"A Giustina","year":"2010","unstructured":"A. Giustina, P. Chanson, M.D. Bronstein, A. Klibanski, S. Lamberts, F.F. Casanueva, P. Trainer, E. Ghigo, K. Ho, S. Melmed, A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95(7), 3141\u20133148 (2010). \n                    https:\/\/doi.org\/10.1210\/jc.2009-2670","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"1615_CR6","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"L. Katznelson, E.R. Laws Jr., S. Melmed, M.E. Molitch, M.H. Murad, A. Utz, J.A.H. Wass, Acromegaly: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(11), 3933\u20133951 (2014). \n                    https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"1615_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nrendo.2014.21","volume":"10","author":"A Giustina","year":"2014","unstructured":"A. Giustina, P. Chanson, D. Kleinberg, M.D. Bronstein, D.R. Clemmons, A. Klibanski, A.J. van der Lely, C.J. Strasburger, S.W. Lamberts, K.K. Ho, F.F. Casanueva, S. Melmed, Expert consensus document: a consensus on the medical treatment of acromegaly. Nat. Rev. Endocrinol. 10(4), 243\u2013248 (2014). \n                    https:\/\/doi.org\/10.1038\/nrendo.2014.21","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"1615_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1210\/er.2009-0033","volume":"31","author":"M Sherlock","year":"2010","unstructured":"M. Sherlock, J. Ayuk, J.W. Tomlinson, A.A. Toogood, A. Aragon-Alonso, M.C. Sheppard, A.S. Bates, P.M. Stewart, Mortality in patients with pituitary disease. Endocr. Rev. 31(3), 301\u2013342 (2010). \n                    https:\/\/doi.org\/10.1210\/er.2009-0033","journal-title":"Endocr. Rev."},{"issue":"12","key":"1615_CR9","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1210\/jc.2014-2670","volume":"99","author":"M Mercado","year":"2014","unstructured":"M. Mercado, B. Gonzalez, G. Vargas, C. Ramirez, A.L. de los Monteros, E. Sosa, P. Jervis, P. Roldan, V. Mendoza, B. Lopez-Felix, G. Guinto, Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J. Clin. Endocrinol. Metab. 99(12), 4438\u20134446 (2014). \n                    https:\/\/doi.org\/10.1210\/jc.2014-2670","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"1615_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11102-013-0506-0","volume":"17","author":"MS Broder","year":"2014","unstructured":"M.S. Broder, M.P. Neary, E. Chang, D. Cherepanov, L. Katznelson, Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases. Pituitary 17(4), 333\u2013341 (2014). \n                    https:\/\/doi.org\/10.1007\/s11102-013-0506-0","journal-title":"Pituitary"},{"issue":"12","key":"1615_CR11","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.18553\/jmcp.2015.21.12.1106","volume":"21","author":"H Placzek","year":"2015","unstructured":"H. Placzek, Y. Xu, Y. Mu, S.M. Begelman, M. Fisher, Clinical and economic burden of commercially insured patients with acromegaly in the United States: a retrospective analysis. J. Manag. Care Spec. Pharm. 21(12), 1106\u20131112 (2015)","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"3","key":"1615_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1530\/EJE-13-0166","volume":"169","author":"F Bogazzi","year":"2013","unstructured":"F. Bogazzi, A. Colao, G. Rossi, M. Lombardi, C. Urbani, C. Sardella, A. Iannelli, I. Scattina, L. Manetti, S. Del Sarto, R. Pivonello, L.F.S. Grasso, I. Lupi, R.S. Auriemma, G. Lombardi, E. Martino, Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study. Eur. J. Endocrinol. 169(3), 367\u2013376 (2013). \n                    https:\/\/doi.org\/10.1530\/eje-13-0166","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"1615_CR13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s11102-015-0700-3","volume":"19","author":"L Varadhan","year":"2016","unstructured":"L. Varadhan, R.C. Reulen, M. Brown, R.N. Clayton, The role of cumulative growth hormone exposure in determining mortality and morbidity in acromegaly: a single centre study. Pituitary 19(3), 251\u2013261 (2016). \n                    https:\/\/doi.org\/10.1007\/s11102-015-0700-3","journal-title":"Pituitary"},{"issue":"5","key":"1615_CR14","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1210\/jc.2004-2297","volume":"90","author":"NR Biermasz","year":"2005","unstructured":"N.R. Biermasz, A.M. Pereira, J.W. Smit, J.A. Romijn, F. Roelfsema, Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J. Clin. Endocrinol. Metab. 90(5), 2731\u20132739 (2005). \n                    https:\/\/doi.org\/10.1210\/jc.2004-2297","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"1615_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1210\/jc.2007-1191","volume":"93","author":"OM Dekkers","year":"2008","unstructured":"O.M. Dekkers, N.R. Biermasz, A.M. Pereira, J.A. Romijn, J.P. Vandenbroucke, Mortality in acromegaly: a meta analysis. J. Clin. Endocrinol. Metab. 93(1), 61\u201367 (2008). \n                    https:\/\/doi.org\/10.1210\/jc.2007-1191","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"1615_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1530\/EJE-08-0267","volume":"159","author":"IM Holdaway","year":"2008","unstructured":"I.M. Holdaway, M.J. Bolland, G.D. Gamble, A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol. 159(2), 89\u201395 (2008). \n                    https:\/\/doi.org\/10.1530\/eje-08-0267","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"1615_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11102-012-0460-2","volume":"17","author":"R Salvatori","year":"2014","unstructured":"R. Salvatori, W.W. Woodmansee, M. Molitch, M.B. Gordon, K.G. Lomax, Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry. Pituitary 17(1), 13\u201321 (2014). \n                    https:\/\/doi.org\/10.1007\/s11102-012-0460-2","journal-title":"Pituitary"},{"issue":"6","key":"1615_CR18","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s11102-017-0821-y","volume":"20","author":"R Salvatori","year":"2017","unstructured":"R. Salvatori, M.B. Gordon, W.W. Woodmansee, A.G. Ioachimescu, D.W. Carver, B. Mirakhur, D. Cox, M.E. Molitch, A multicenter, observational study of lanreotide depot\/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry. Pituitary 20(6), 605\u2013618 (2017). \n                    https:\/\/doi.org\/10.1007\/s11102-017-0821-y","journal-title":"Pituitary"},{"issue":"2","key":"1615_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1530\/eje-12-0147","volume":"167","author":"KMJA Claessen","year":"2012","unstructured":"K.M.J.A. Claessen, S.R. Ramautar, A.M. Pereira, J.W.A. Smit, F. Roelfsema, J.A. Romijn, H.M. Kroon, M. Kloppenburg, N.R. Biermasz, Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study. Eur. J. Endocrinol. 167(2), 235\u2013244 (2012). \n                    https:\/\/doi.org\/10.1530\/eje-12-0147","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"1615_CR20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1530\/EJE-08-0442","volume":"159","author":"MV Davi","year":"2008","unstructured":"M.V. Davi, L. Dalle Carbonare, A. Giustina, M. Ferrari, A. Frigo, V. Lo Cascio, G. Francia, Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur. J. Endocrinol. 159(5), 533\u2013540 (2008). \n                    https:\/\/doi.org\/10.1530\/eje-08-0442","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"1615_CR21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1530\/EJE-07-0358","volume":"157","author":"M Bex","year":"2007","unstructured":"M. Bex, R. Abs, G. T. Sjoen, J. Mockel, B. Velkeniers, K. Muermans, D. Maiter, AcroBel\u2014the Belgian registry on acromegaly: a survey of the \u2018real-life\u2019 outcome in 418 acromegalic subjects. Eur. J. Endocrinol. 157(4), 399\u2013409 (2007). \n                    https:\/\/doi.org\/10.1530\/eje-07-0358","journal-title":"Eur. J. Endocrinol."},{"key":"1615_CR22","doi-asserted-by":"publisher","first-page":"(Suppl 1), 11","DOI":"10.1530\/EJE-09-0333","volume":"161","author":"T Brue","year":"2009","unstructured":"T. Brue, F. Castinetti, F. Lundgren, M. Koltowska-Haggstrom, P. Petrossians, Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY. Eur. J. Endocrinol. 161, (Suppl 1), 11\u2013S17 (2009). \n                    https:\/\/doi.org\/10.1530\/eje-09-0333","journal-title":"Eur. J. Endocrinol."},{"issue":"10","key":"1615_CR23","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1210\/jc.2009-0941","volume":"94","author":"A Colao","year":"2009","unstructured":"A. Colao, R.S. Auriemma, M. Galdiero, G. Lombardi, R. Pivonello, Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J. Clin. Endocrinol. Metab. 94(10), 3746\u20133756 (2009). \n                    https:\/\/doi.org\/10.1210\/jc.2009-0941","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"1615_CR24","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1530\/EJE-11-0408","volume":"165","author":"A Colao","year":"2011","unstructured":"A. Colao, R. Pivonello, L.F. Grasso, R.S. Auriemma, M. Galdiero, S. Savastano, G. Lombardi, Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. Eur. J. Endocrinol. 165(5), 713\u2013721 (2011). \n                    https:\/\/doi.org\/10.1530\/eje-11-0408","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"1615_CR25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11102-011-0318-z","volume":"15","author":"A Colao","year":"2012","unstructured":"A. Colao, Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary 15(1), 50\u201358 (2012). \n                    https:\/\/doi.org\/10.1007\/s11102-011-0318-z","journal-title":"Pituitary"},{"issue":"3","key":"1615_CR26","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s12020-016-0995-5","volume":"55","author":"RS Auriemma","year":"2017","unstructured":"R.S. Auriemma, L.F. Grasso, M. Galdiero, M. Galderisi, C. Pivonello, C. Simeoli, M.C. De Martino, R. Ferrigno, M. Negri, C. de Angelis, R. Pivonello, A. Colao, Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine 55(3), 872\u2013884 (2017). \n                    https:\/\/doi.org\/10.1007\/s12020-016-0995-5","journal-title":"Endocrine"},{"issue":"2","key":"1615_CR27","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1210\/jc.2013-2450","volume":"99","author":"M Sherlock","year":"2014","unstructured":"M. Sherlock, R.C. Reulen, A. Aragon-Alonso, J. Ayuk, R.N. Clayton, M.C. Sheppard, M.M. Hawkins, A.S. Bates, P.M. Stewart, A paradigm shift in the monitoring of patients with acromegaly: last available growth hormone may overestimate risk. J. Clin. Endocrinol. Metab. 99(2), 478\u2013485 (2014). \n                    https:\/\/doi.org\/10.1210\/jc.2013-2450","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"1615_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-017-0166-6","volume":"17","author":"JD Carmichael","year":"2017","unstructured":"J.D. Carmichael, M.S. Broder, D. Cherepanov, E. Chang, A. Mamelak, Q. Said, M.P. Neary, V. Bonert, The association between biochemical control and cardiovascular risk factors in acromegaly. BMC Endocr. Disord. 17(1), 15 (2017). \n                    https:\/\/doi.org\/10.1186\/s12902-017-0166-6","journal-title":"BMC Endocr. Disord."},{"issue":"11","key":"1615_CR29","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1210\/jc.2016-1937","volume":"101","author":"LA Portocarrero-Ortiz","year":"2016","unstructured":"L.A. Portocarrero-Ortiz, A. Vergara-Lopez, M. Vidrio-Velazquez, A.M. Uribe-Diaz, A. Garcia-Dominguez, A.A. Reza-Albarran, D. Cuevas-Ramos, V. Melgar, J. Talavera, A.J. Rivera-Hernandez, C.V. Valencia-Mendez, M. Mercado, The Mexican Acromegaly Registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J. Clin. Endocrinol. Metab. 101(11), 3997\u20134004 (2016). \n                    https:\/\/doi.org\/10.1210\/jc.2016-1937","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"1615_CR30","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1530\/eje.0.1510439","volume":"151","author":"A Mestron","year":"2004","unstructured":"A. Mestron, S.M. Webb, R. Astorga, P. Benito, M. Catala, S. Gaztambide, J.M. Gomez, I. Halperin, T. Lucas-Morante, B. Moreno, G. Obiols, P. de Pablos, C. Paramo, A. Pico, E. Torres, C. Varela, J.A. Vazquez, J. Zamora, M. Albareda, M. Gilabert, Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur. J. Endocrinol. 151(4), 439\u2013446 (2004)","journal-title":"Eur. J. Endocrinol."},{"key":"1615_CR31","doi-asserted-by":"publisher","first-page":"573643","DOI":"10.1155\/2015\/573643","volume":"2015","author":"X Guo","year":"2015","unstructured":"X. Guo, L. Gao, S. Zhang, Y. Li, Y. Wu, L. Fang, K. Deng, Y. Yao, W. Lian, R. Wang, B. Xing, Cardiovascular system changes and related risk factors in acromegaly patients: a case-control study. Int J. Endocrinol. 2015, 573643 (2015). \n                    https:\/\/doi.org\/10.1155\/2015\/573643\n                    \n                  . doi: 573610.571155\/572015\/573643","journal-title":"Int J. Endocrinol."},{"issue":"12","key":"1615_CR32","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1210\/jc.2015-2675","volume":"100","author":"CM Santos Silva dos","year":"2015","unstructured":"C.M. dos Santos Silva, I. Gottlieb, I. Volschan, L. Kasuki, L. Warszawski, G.A. Balarini Lima, S.S. Xavier, R.C. Pedrosa, L.V. Neto, M.R. Gadelha, Low frequency of cardiomyopathy using cardiac magnetic resonance imaging in an acromegaly contemporary cohort. J. Clin. Endocrinol. Metab. 100(12), 4447\u20134455 (2015). \n                    https:\/\/doi.org\/10.1210\/jc.2015-2675","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"1615_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000438903","volume":"103","author":"AS Powlson","year":"2016","unstructured":"A.S. Powlson, M. Gurnell, Cardiovascular disease and sleep-disordered breathing in acromegaly. Neuroendocrinology 103(1), 75\u201385 (2016). \n                    https:\/\/doi.org\/10.1159\/000438903","journal-title":"Neuroendocrinology"},{"issue":"2","key":"1615_CR34","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1210\/jc.2009-1912","volume":"95","author":"P Attal","year":"2010","unstructured":"P. Attal, P. Chanson, Endocrine aspects of obstructive sleep apnea. J. Clin. Endocrinol. Metab. 95(2), 483\u2013495 (2010). \n                    https:\/\/doi.org\/10.1210\/jc.2009-1912","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"1615_CR35","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1183\/13993003.01229-2016","volume":"48","author":"LM Galerneau","year":"2016","unstructured":"L.M. Galerneau, J.L. Pepin, A.L. Borel, O. Chabre, M. Sapene, B. Stach, J. Girey-Rannaud, N. Arnol, R. Tamisier, P. Caron, Acromegaly in sleep apnoea patients: a large observational study of 755 patients. Eur. Respir. J. 48(5), 1489\u20131492 (2016). \n                    https:\/\/doi.org\/10.1183\/13993003.01229-2016","journal-title":"Eur. Respir. J."},{"issue":"6","key":"1615_CR36","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1530\/EJE-10-1050","volume":"164","author":"S Fieffe","year":"2011","unstructured":"S. Fieffe, I. Morange, P. Petrossians, P. Chanson, V. Rohmer, C. Cortet, F. Borson-Chazot, T. Brue, B. Delemer, Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur. J. Endocrinol. 164(6), 877\u2013884 (2011). \n                    https:\/\/doi.org\/10.1530\/eje-10-1050","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"1615_CR37","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1055\/s-0035-1569277","volume":"48","author":"C Jonas","year":"2016","unstructured":"C. Jonas, D. Maiter, O. Alexopoulou, Evolution of glucose tolerance after treatment of acromegaly: a study in 57 patients. Horm. Metab. Res 48(5), 299\u2013305 (2016). \n                    https:\/\/doi.org\/10.1055\/s-0035-1569277","journal-title":"Horm. Metab. Res"},{"issue":"5","key":"1615_CR38","doi-asserted-by":"publisher","first-page":"501","DOI":"10.5603\/EP.a2016.0031","volume":"67","author":"C Wen-Ko","year":"2016","unstructured":"C. Wen-Ko, C. Szu-Tah, L. Feng-Hsuan, C. Chen-Nen, W. Ming-Hsu, L. Jen-Der, The impact of diabetes mellitus on the survival of patients with acromegaly. Endokrynol. Pol. 67(5), 501\u2013506 (2016). \n                    https:\/\/doi.org\/10.5603\/EP.a2016.0031","journal-title":"Endokrynol. Pol."},{"issue":"5","key":"1615_CR39","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1210\/jc.2008-2332","volume":"94","author":"G Mazziotti","year":"2009","unstructured":"G. Mazziotti, I. Floriani, S. Bonadonna, V. Torri, P. Chanson, A. Giustina, Effects of somatostatin analogs on glucose homeostasis: a meta analysis of acromegaly studies. J. Clin. Endocrinol. Metab. 94(5), 1500\u20131508 (2009). \n                    https:\/\/doi.org\/10.1210\/jc.2008-2332","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"1615_CR40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1530\/EJE-13-0032","volume":"169","author":"C Urbani","year":"2013","unstructured":"C. Urbani, C. Sardella, A. Calevro, G. Rossi, I. Scattina, M. Lombardi, I. Lupi, L. Manetti, E. Martino, F. Bogazzi, Effects of medical therapies for acromegaly on glucose metabolism. Eur. J. Endocrinol. 169(1), 99\u2013108 (2013). \n                    https:\/\/doi.org\/10.1530\/eje-13-0032","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"1615_CR41","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1210\/jc.2013-3318","volume":"99","author":"PJ Caron","year":"2014","unstructured":"P.J. Caron, J.S. Bevan, S. Petersenn, D. Flanagan, A. Tabarin, G. Pr\u00e9vost, P. Maisonobe, A. Clermont, Tumor shrinkage with lanreotide autogel 120\u2009mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J. Clin. Endocrinol. Metab. 99(4), 1282\u20131290 (2014). \n                    https:\/\/doi.org\/10.1210\/jc.2013-3318","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"1615_CR42","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/cen.13285","volume":"86","author":"PJ Caron","year":"2017","unstructured":"P.J. Caron, S. Petersenn, A. Houchard, C. Sert, J.S. Bevan, Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naive patients with acromegaly: data from the PRIMARYS study. Clin. Endocrinol. (Oxf.) 86(4), 541\u2013551 (2017). \n                    https:\/\/doi.org\/10.1111\/cen.13285","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"1615_CR43","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s12020-016-0895-8","volume":"53","author":"HA Schmid","year":"2016","unstructured":"H.A. Schmid, T. Brue, A. Colao, M.R. Gadelha, I. Shimon, K. Kapur, A.M. Pedroncelli, M. Fleseriu, Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine 53, 210\u2013219 (2016). \n                    https:\/\/doi.org\/10.1007\/s12020-016-0895-8","journal-title":"Endocrine"},{"issue":"12","key":"1615_CR44","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1210\/jcem.85.12.7017","volume":"85","author":"KC Leung","year":"2000","unstructured":"K.C. Leung, N. Doyle, M. Ballesteros, M.J. Waters, K.K. Ho, Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J. Clin. Endocrinol. Metab. 85(12), 4712\u20134720 (2000). \n                    https:\/\/doi.org\/10.1210\/jcem.85.12.7017","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"1615_CR45","doi-asserted-by":"publisher","first-page":"E51","DOI":"10.1210\/jc.2012-2896","volume":"98","author":"A Ciresi","year":"2013","unstructured":"A. Ciresi, M.C. Amato, R. Pivonello, E. Nazzari, L.F. Grasso, F. Minuto, D. Ferone, A. Colao, C. Giordano, The metabolic profile in active acromegaly is gender-specific. J. Clin. Endocrinol. Metab. 98(1), E51\u2013E59 (2013). \n                    https:\/\/doi.org\/10.1210\/jc.2012-2896","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"1615_CR46","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1210\/jc.2004-0501","volume":"90","author":"HK Gleeson","year":"2005","unstructured":"H.K. Gleeson, C.A. Lissett, S.M. Shalet, Insulin-like growth factor-I response to a single bolus of growth hormone is increased in obesity. J. Clin. Endocrinol. Metab. 90(2), 1061\u20131067 (2005). \n                    https:\/\/doi.org\/10.1210\/jc.2004-0501","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"1615_CR47","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/S0026-0495(96)90029-3","volume":"45","author":"SY Nam","year":"1996","unstructured":"S.Y. Nam, E.J. Lee, K.R. Kim, H.C. Lee, M.S. Nam, J.H. Cho, K.B. Huh, Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity. Metabolism 45(5), 594\u2013597 (1996). \n                    https:\/\/doi.org\/10.1016\/S0026-0495(96)90029-3","journal-title":"Metabolism"},{"issue":"6","key":"1615_CR48","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1530\/EJE-11-0098","volume":"164","author":"M Matta","year":"2011","unstructured":"M. Matta, V. Bongard, S. Grunenwald, J.-C. Maiza, A. Bennet, P. Caron, Clinical and metabolic characteristics of acromegalic patients with high IGF1\/normal GH levels during somatostatin analog treatment. Eur. J. Endocrinol. 164(6), 885\u2013889 (2011). \n                    https:\/\/doi.org\/10.1530\/eje-11-0098","journal-title":"Eur. J. Endocrinol."},{"issue":"22","key":"1615_CR49","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.3748\/wjg.14.3484","volume":"14","author":"T Rokkas","year":"2008","unstructured":"T. Rokkas, D. Pistiolas, P. Sechopoulos, G. Margantinis, G. Koukoulis, Risk of colorectal neoplasm in patients with acromegaly: A meta-analysis. World J. Gastroenterol. 14(22), 3484\u20133489 (2008). \n                    https:\/\/doi.org\/10.3748\/wjg.14.3484","journal-title":"World J. Gastroenterol."},{"issue":"11-12","key":"1615_CR50","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1055\/s-2004-814150","volume":"35","author":"AG Renehan","year":"2003","unstructured":"A.G. Renehan, J. O\u2019Connell, D. O\u2019Halloran, F. Shanahan, C.S. Potten, S.T. O\u2019Dwyer, S.M. Shalet, Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. Horm. Metab. Res. 35(11-12), 712\u2013725 (2003). \n                    https:\/\/doi.org\/10.1055\/s-2004-814150","journal-title":"Horm. Metab. Res."},{"issue":"1","key":"1615_CR51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/(SICI)1097-0215(19990924)83:1<15::AID-IJC4>3.0.CO;2-Y","volume":"83","author":"O Manousos","year":"1999","unstructured":"O. Manousos, J. Souglakos, C. Bosetti, A. Tzonou, V. Chatzidakis, D. Trichopoulos, H.O. Adami, C. Mantzoros, IGF-I and IGF-II in relation to colorectal cancer. Int. J. Cancer 83(1), 15\u201317 (1999)","journal-title":"Int. J. Cancer"},{"issue":"suppl 5","key":"1615_CR52","doi-asserted-by":"publisher","first-page":"v13","DOI":"10.1136\/gut.51.suppl_5.v13","volume":"51","author":"PJ Jenkins","year":"2002","unstructured":"P.J. Jenkins, P.D. Fairclough, Screening guidelines for colorectal cancer and polyps in patients with acromegaly. Gut 51(suppl 5), v13\u2013v14 (2002). \n                    https:\/\/doi.org\/10.1136\/gut.51.suppl_5.v13","journal-title":"Gut"},{"issue":"1","key":"1615_CR53","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1530\/EJE-09-1080","volume":"163","author":"D Dworakowska","year":"2010","unstructured":"D. Dworakowska, M. Gueorguiev, P. Kelly, J.P. Monson, G.M. Besser, S.L. Chew, S.A. Akker, W.M. Drake, P.D. Fairclough, A.B. Grossman, P.J. Jenkins, Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines. Eur. J. Endocrinol. 163(1), 21\u201328 (2010). \n                    https:\/\/doi.org\/10.1530\/eje-09-1080","journal-title":"Eur. J. Endocrinol."},{"key":"1615_CR54","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1155\/2016\/5156295","volume":"2016","author":"MB Gordon","year":"2016","unstructured":"M.B. Gordon, S. Nakhle, W.H. Ludlam, Patients with acromegaly presenting with colon cancer: a case series.Case Rep. Endocrinol. 2016, 4 (2016). \n                    https:\/\/doi.org\/10.1155\/2016\/5156295","journal-title":"Case Rep. Endocrinol."},{"issue":"4","key":"1615_CR55","doi-asserted-by":"publisher","first-page":"437","DOI":"10.4103\/2230-8210.183455","volume":"20","author":"P Agarwal","year":"2016","unstructured":"P. Agarwal, P. Rai, M. Jain, S. Mishra, U. Singh, S.K. Gupta, Prevalence of colonic polyp and its predictors in patients with acromegaly. Indian J. Endocrinol. Metab. 20(4), 437\u2013442 (2016). \n                    https:\/\/doi.org\/10.4103\/2230-8210.183455","journal-title":"Indian J. Endocrinol. Metab."},{"issue":"3","key":"1615_CR56","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/j.1365-2265.2009.03547.x","volume":"71","author":"S Petersenn","year":"2009","unstructured":"S. Petersenn, M. Buchfelder, B. Gerbert, H. Franz, H.J. Quabbe, H.M. Schulte, M. Grussendorf, M. Reincke, Age and sex as predictors of biochemical activity in acromegaly: analysis of 1485 patients from the German Acromegaly Register. Clin. Endocrinol. (Oxf.) 71(3), 400\u2013405 (2009). \n                    https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03547.x","journal-title":"Clin. Endocrinol. (Oxf.)"},{"issue":"11","key":"1615_CR57","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1210\/jc.2009-1097","volume":"94","author":"M Sherlock","year":"2009","unstructured":"M. Sherlock, R.C. Reulen, A.A. Alonso, J. Ayuk, R.N. Clayton, M.C. Sheppard, M.M. Hawkins, A.S. Bates, P.M. Stewart, ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J. Clin. Endocrinol. Metab. 94(11), 4216\u20134223 (2009). \n                    https:\/\/doi.org\/10.1210\/jc.2009-1097","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"1615_CR58","doi-asserted-by":"publisher","first-page":"E1120","DOI":"10.1210\/jc.2010-2669","volume":"96","author":"AK Annamalai","year":"2011","unstructured":"A.K. Annamalai, E.L. Gayton, A. Webb, D.J. Halsall, C. Rice, F. Ibram, A.N. Chaudhry, H.L. Simpson, L. Berman, M. Gurnell, Increased prevalence of gallbladder polyps in acromegaly. J. Clin. Endocrinol. Metab. 96(7), E1120\u2013E1125 (2011). \n                    https:\/\/doi.org\/10.1210\/jc.2010-2669","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-018-1615-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-018-1615-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-018-1615-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T21:25:48Z","timestamp":1557955548000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-018-1615-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,16]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["1615"],"URL":"https:\/\/doi.org\/10.1007\/s12020-018-1615-3","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"type":"print","value":"1355-008X"},{"type":"electronic","value":"1559-0100"}],"subject":[],"published":{"date-parts":[[2018,5,16]]},"assertion":[{"value":"1 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"WWW: Clinical trial investigator: Ipsen, Versartis; Advisor\/consultant: Ipsen. MBG: Research support: Chiasma, Corcept, Ipsen, Novartis, Novo Nordisk, Pfizer, OPKO, Strongbridge, Teva. MEM: Research support: Bayer, Ipsen, Johnson & Johnson, Novartis, Novo Nordisk, Prolor; Advisor\/consultant: Corcept, Ipsen, Merck, Novartis, Novo Nordisk, Pfizer. AGI: Research support: Chiasma, Ipsen, Novartis, Pfizer; Advisor\/consultant: Chiasma, Ionis, Ipsen, Pfizer. DWC: Ipsen consultant. BM, DC: Full-time employees: Ipsen Biopharmaceuticals, Inc. RS: Research support: Chiasma, Novartis, Novo Nordisk, Pfizer, Prolor, Strongbridge; Advisor\/consultant: Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The SODA study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice Guidelines, current Food and Drug Administration regulations and guidelines, local ethical and legal requirements, and the United States Code of Federal Regulations and the Health Insurance Portability and Accountability Act for the collection, transmission, and storage of study data. All procedures performed involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Signed informed consent was obtained from each patient at study inclusion.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}